Company / Shareholders' Equity
Xenon Pharmaceuticals Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$581.8M
FY2025
5-year range
$550.0M / $927.9M
FY2021-FY2025
Trend
-22.9%
vs FY2024
Sector context
#84 of 213
Health Care
What the data says
At $582M, Xenon Pharmaceuticals Inc.'s shareholders' equity ranks #84 of 213 in the Health Care sector. Shareholders' Equity has fluctuated over the past 10 years, ranging from $64M in FY2017 to $928M in FY2023.
Based on SEC 10-K filings.
$582M in FY2025 with a 5-year CAGR of +27.7%.
Declined from $928M to $582M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -6.9%
- 5-Year CAGR
- +27.7%
- 10-Year CAGR
- -
Sector benchmark
#84 of 213 in Health CareTop 39% of 213This company $581.8M Sector average $2.5B
▼
-77.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +27.7%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 22.9% year-over-year.
- Ranks #84 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $581.8M | -22.9% |
| FY2024 | $754.9M | -18.6% |
| FY2023 | $927.9M | +28.6% |
| FY2022 | $721.5M | +31.2% |
| FY2021 | $550.0M | +221.0% |
| FY2020 | $171.4M | +86.3% |
| FY2019 | $92.0M | -11.0% |
| FY2018 | $103.3M | +61.6% |
| FY2017 | $63.9M | +0.0% |
| FY2016 | $63.9M | +4.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026